Literature DB >> 10640784

Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses.

J Alexander1, M F del Guercio, A Maewal, L Qiao, J Fikes, R W Chesnut, J Paulson, D R Bundle, S DeFrees, A Sette.   

Abstract

Linear carbohydrate-peptide constructs based on the 13 amino acid nonnatural pan DR epitope (PADRE) and carbohydrate B cell epitopes are demonstrated to be potent immunogens. These data support our belief that PADRE should be considered as an alternative to more complex carriers for use in prophylaxis and therapeutic vaccines. Two model carbohydrate-PADRE glycoconjugates were used to demonstrate that PADRE could effectively provide T cell help for carbohydrate-specific Ab responses. Conjugates of PADRE covalently linked to the human milk oligosaccharide, lacto-N-fucopentose II or a dodecasaccharide derived from Salmonella typhimurium O-Ag induced high titer IgG Ab responses in mice, which were comparable to glycoconjugates employing human serum albumin (HSA) as the carrier protein. Different adjuvants, in combination with PADRE conjugates, allowed for the modulation of the isotype profile with alum supporting an IgG1 profile; QS-21 an IgG2a, 2b profile, while an alum/QS-21 mixture generated a balanced IgG1/IgG2b isotype profile. As defined by binding to synthetic glycoconjugates, dodecasaccharide-specific Abs exhibited fine specificity similar to protective polyclonal Ab responses previously reported for dodecasaccharide-protein conjugates. The same Abs bound to intact S. typhimurium cells, suggesting that biologically relevant specificities were produced. The affinity of the dodecasaccharide-specific Abs was further shown to be comparable to that of a well-characterized, high affinity monoclonal anti-carbohydrate Ab recognizing the same epitope.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10640784     DOI: 10.4049/jimmunol.164.3.1625

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  56 in total

1.  How much help does a vaccine-induced T-cell response need?

Authors:  J S Weber; J J Mulé
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

Review 2.  Carbohydrate-based cancer vaccines: target cancer with sugar bullets.

Authors:  Chang-Cheng Liu; Xin-Shan Ye
Journal:  Glycoconj J       Date:  2012-06-06       Impact factor: 2.916

3.  Impairment by mucosal adjuvants and cross-reactivity with variant peptides of the mucosal immunity induced by injection of the fusion peptide PADRE-ELDKWA.

Authors:  Nipa Decroix; Perayot Pamonsinlapatham; Cahn P Quan; Jean-Pierre Bouvet
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

4.  N19 polyepitope as a carrier for enhanced immunogenicity and protective efficacy of meningococcal conjugate vaccines.

Authors:  Karin Baraldo; Elena Mori; Antonella Bartoloni; Roberto Petracca; Aldo Giannozzi; Francesco Norelli; Rino Rappuoli; Guido Grandi; Giuseppe Del Giudice
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

5.  Low concentrations of anti-Aβ antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology.

Authors:  Nina Movsesyan; Hayk Davtyan; Mikayel Mkrtichyan; Irina Petrushina; Tigran Tiraturyan; Ted Ross; Michael G Agadjanyan; Anahit Ghochikyan; David H Cribbs
Journal:  Hum Gene Ther       Date:  2010-11       Impact factor: 5.695

6.  Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein.

Authors:  Karin Baraldo; Elena Mori; Antonella Bartoloni; Francesco Norelli; Guido Grandi; Rino Rappuoli; Oretta Finco; Giuseppe Del Giudice
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 7.  Recent progress in adjuvant discovery for peptide-based subunit vaccines.

Authors:  Fazren Azmi; Abdullah Al Hadi Ahmad Fuaad; Mariusz Skwarczynski; Istvan Toth
Journal:  Hum Vaccin Immunother       Date:  2013-12-03       Impact factor: 3.452

8.  Robust immune responses elicited by a fully synthetic three-component vaccine.

Authors:  Sampat Ingale; Margreet A Wolfert; Jidnyasa Gaekwad; Therese Buskas; Geert-Jan Boons
Journal:  Nat Chem Biol       Date:  2007-09-02       Impact factor: 15.040

Review 9.  Amyloid-beta immunization in Alzheimer's disease transgenic mouse models and wildtype mice.

Authors:  Cynthia A Lemere; Edward T Spooner; Jodi F Leverone; Chica Mori; Melitza Iglesias; Jeanne K Bloom; Timothy J Seabrook
Journal:  Neurochem Res       Date:  2003-07       Impact factor: 3.996

10.  Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors.

Authors:  Sampat Ingale; Margreet A Wolfert; Therese Buskas; Geert-Jan Boons
Journal:  Chembiochem       Date:  2009-02-13       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.